WuXi AppTec reported H1 2026 revenue of RMB 28.897 billion, up 38.93% year on year, and net profit of RMB 11.08 billion, up 29.43%. The company raised its capital expenditure budget to RMB 7.5-8.5 billion and adjusted free cash flow forecast to RMB 13.5-14.5 billion. Order backlog rose 25.2% to RMB 66.43 billion. WuXi AppTec also disclosed it is challenging its inclusion on the U. S. Department of Defense's Chinese Military Companies list through litigation.
Jitai Technology announced on the Hong Kong Stock Exchange that its self-developed AiTEM artificial intelligence formulation innovation platform will be locally deployed at Jiangsu Hengrui Medicine Co. , Ltd. The deployment is intended to accelerate the efficiency of drug formulation development. The collaboration centres on the AI formulation platform field, with the aim of enhancing the automation and intelligence level of the pharmaceutical research and development process through technology deployment.